Compare Incyte Corporation (INCY) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kaltura Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Kaltura Inc trades at $1.63 (market cap $249.42M). The key difference: Incyte Corporation is far larger — about 98.4× Kaltura Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| INCY | KLTR | |
|---|---|---|
Market Cap | $24.54B | $249.42M |
Sector | Health | Technology |
52-Week High | $129.93 | $1.89 |
52-Week Low | $81.61 | $1.08 |
Enterprise Value | $20.04B | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Kaltura (KLTR) trades at $1.58, down 3.66% today, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent Q2 2026 earnings beat expectations, and the company has received multiple industry recognitions for its AI and video platform leadership.
While Kaltura demonstrates operational improvement and strong analyst support (44% buy ratings), significant risks remain including persistent negative ROE (-134%), high valuation multiples (EV/EBITDA 336x), and insider selling. The stock offers speculative upside if AI initiatives drive profitability, but requires careful risk management given current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
